Skip Navigation

The push back on Sovaldi

The push back on Sovaldi

Insurance companies are hurting from the high cost of hepatitis C drug Sovaldi. Arthur Caplan, NYU Langone Medical Center, and CNBC's Bertha Coombs, share their opinions.

03:33

Fri, Jul 25 20142:52 PM EDT

The Fed won't cut interest rates this year, says Apollo Global's Torsten Slok

The Fed won't cut interest rates this year, says Apollo Global's Torsten Slok

5 hours ago

Tesla's big gamble: Full Self-Driving in the wild

Tesla's big gamble: Full Self-Driving in the wild

May will be a month that determines how returns for the year will look: NYU's Aswath Damodaran

May will be a month that determines how returns for the year will look: NYU's Aswath Damodaran

Black-owned businesses still face headwinds in obtaining capital

Black-owned businesses still face headwinds in obtaining capital

Stocks picks for companies with 'boomerang CEOs'

Stocks picks for companies with 'boomerang CEOs'

The Fed won't cut interest rates this year, says Apollo Global's Torsten Slok

The Fed won't cut interest rates this year, says Apollo Global's Torsten Slok

5 hours ago

Tesla's big gamble: Full Self-Driving in the wild

Tesla's big gamble: Full Self-Driving in the wild

May will be a month that determines how returns for the year will look: NYU's Aswath Damodaran

May will be a month that determines how returns for the year will look: NYU's Aswath Damodaran

Black-owned businesses still face headwinds in obtaining capital

Black-owned businesses still face headwinds in obtaining capital

Stocks picks for companies with 'boomerang CEOs'

Stocks picks for companies with 'boomerang CEOs'